Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents and Drug Development
  • Published:

Experimental use and the orphan drug act: A biotechnology conundrum

Nature Biotechnology volume 14, pages 511–512 (1996)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Holme Roberts and Owen LLC. The opinions expressed are those of the author and not necessarily those of Holme Roberts and Owen LLC or its clients.

  2. For a history of the enactment of this section, see Neesemann, C.E. and Hough, J.E. 1995. The Infringement Exemption. Bio/Technology 13: 1065–66.

    Article  CAS  Google Scholar 

  3. 25 USPQ2d 1196(Fed.Cir.1992).

  4. 21 U.S.C. §§ 360aa–360ee.

  5. See Pub. L No. 97-414, § 2(a), 96 Stat. 2049, 2050. (1983).

  6. Genentech, Inc. V. Otis R. Bowen, 676 F. Supp. 301 (D.D.C. 1987).

  7. There is legislative history that indicates Congress intended that such a conflict shouldn't arise; see H.R. Rep. 153, 99th Cong., 1st Sess., reprinted in 1985 U.S. Code Cong. & Admin. News 301.

  8. Amgen Inc. v. Chugui Pharmaceutical Co., Ltd. 18 USPQ2d 1016 (Fed.Cir 1991) cert. denied 116 LE.d 2d 132,112 S.Ct. 169 (US 1991).

  9. Article 1,§ 8.

  10. Chartex International PLC v. M.D. Personal Products Corporation August 12, US App. LEXIS 20560 (Fed. Cir. 1993).

  11. Abtox, Inc. v. Exitron Corporation 35 USPQ2d 1508 (D.Mass. 1995).

  12. Infinitech, Inc. v. Vitrophage, Inc. 30 USPQ2d 1201 (N.D. III. 1994).

  13. Farmaceutisk Laboratorium Ferring v. Solvay Pharmaceutical, Inc., 25 USPQ2d 1344 (N.D. Georgia 1992).

Download references

Author information

Author notes

  1. Paul J. Koivuniemi: Paul J. Koivuniemi was formerly patent counsel and general counsel at Synergen, Inc.

Authors and Affiliations

  1. Special Counsel at Holme Roberts & Owen, 1401 Pearl St. Suite 400, Boulder, CO, 80302

    Paul J. Koivuniemi

Authors
  1. Paul J. Koivuniemi
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koivuniemi, P. Experimental use and the orphan drug act: A biotechnology conundrum. Nat Biotechnol 14, 511–512 (1996). https://doi.org/10.1038/nbt0496-511

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0496-511

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing